Grant Shoebridge PhD

Principal

Grant has over a decade of experience in pharmaceutical and biotechnology-related intellectual property.


  • Grant is a principal with over a decade of experience in pharmaceutical and biotechnology-related intellectual property. Grant specialises in drafting of patent specifications,  prosecution and opposition matters relating to molecular biology, cell biology, immunology, pharmaceuticals, medical devices, agricultural technology, and diagnostic technology. He also heads Shelston IP’s immunology expertise.

    Grant has particular expertise in securing extensions of term on pharmaceutical patents and advising on patent validity and infringement. He has also acted as an advisor in relation to a number of Federal Court litigation matters.

    Grant has a PhD in immunology and spent 15 years working in a range of medical research fields including, HIV, cancer and vaccine-based research. He also has industry-based expertise, having worked for two biotechnology companies in London and Switzerland on the development of diagnostics.

    Grant played an active role in the “gene patent” debate in Australia. This included numerous TV, radio and print media appearances as well as involvement in IPTA’s application to be heard as amicus curiae in the High Court appeal in D’Arcy v Myriad Genetics Inc. Grant is considered to be a leading Australian authority on gene-based patentable subject matter and most recently successfully acted for the Applicant in Arrowhead Research Corporation [2016] APO 70, which set an important legal precedent in relation to the patentability of gene-based pharmaceutical inventions in Australia.

    From 2010 to 2013, Grant was a lecturer for the course “Interpretation and Validity of Patent Specifications” which is part of  the the University of Technology, Sydney postgraduate law program, and the Masters in Intellectual Property, which provides a pathway to registration for Australian patent attorneys. Grant is currently a lecturer for the University of NSW course “ Myths and Realities of Personalised Medicine: The Genetic Revolution”.

    Grant is a Fellow and a Council Member of the Institute of Patent and Trade Mark Attorneys of Australia.

    Grant is recommended in the 2018 Intellectual Asset Management (IAM Patent 1000 2018). It was reported “With unparalleled knowledge in gene-based patentable subject matter, Grant Shoebridge most recently established precedent in the influential Arrowhead decision.”

    He is also named as a noteworthy attorney for Intellectual Property in the pharmaceutical and biotech industries in The Legal 500 Asia Pacific 2018.

    Qualifications

    • Doctor of Philosophy (Molecular Immunology), University of Technology Sydney
    • Master of Industrial Property, University of Technology Sydney
    • Bachelor of Science (Molecular and Cell Biology) (Honours), Macquarie University
    • Registered Patent Attorney (Australia & New Zealand).

    Associations

    • Fellow, Institute of Patent and Trade Mark Attorneys of Australia
    • Intellectual Property Society of Australia and New Zealand
    • Australian Biotechnology Association (AusBiotech).

    2017 Biotechnology awards

    Shelston IP has won the ‘Best Biotechnology & Life Sciences Patent Prosecutor – Australia‘  award from Global Health and Pharma